Glenmark Pharmaceuticals Shareholding

Glenmark Pharmaceuticals Ltd Shareholding Pattern

The Glenmark Pharmaceuticals Ltd shareholding pattern provides detailed insights into how ownership of the company is distributed among promoters, FIIs, DIIs, public investors, and government entities. Tracking the Glenmark Pharmaceuticals Ltd shareholding structure helps investors understand institutional confidence, promoter commitment, and overall market sentiment.

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) operates in the Health technology sector and Pharmaceuticals: major industry. Monitoring the Glenmark Pharmaceuticals Ltd shareholding pattern regularly allows investors to analyze ownership trends and make informed investment decisions.

Glenmark Pharmaceuticals Ltd Shareholding Pattern (Latest)

The latest Glenmark Pharmaceuticals Ltd shareholding for Dec 2025 is:

• Promoters: 46.65%
• FII: 19.20%
• DII: 20.09%
• Public: 14.02%
• Government: 0.04%

Promoter holding in Glenmark Pharmaceuticals Ltd has increased, indicating strong confidence from company promoters.

Glenmark Pharmaceuticals Ltd Promoter Holding Trend

Promoter shareholding plays a crucial role in evaluating management confidence in Glenmark Pharmaceuticals Ltd.

• Dec 2025: 46.65%
• Sept 2025: 46.65%
• Jun 2025: 46.65%
• Mar 2025: 46.65%
• Dec 2024: 46.65%

Promoter stake in Glenmark Pharmaceuticals Ltd has increased, indicating strong long-term confidence.

Glenmark Pharmaceuticals Ltd FII Shareholding Trend

Foreign Institutional Investors (FIIs) reflect global investor sentiment toward Glenmark Pharmaceuticals Ltd.

• Dec 2025: 19.20%
• Sept 2025: 20.73%
• Jun 2025: 20.62%
• Mar 2025: 23.16%
• Dec 2024: 23.51%

FII holding has declined, suggesting cautious sentiment among foreign investors.

Glenmark Pharmaceuticals Ltd DII Shareholding Trend

Domestic Institutional Investors (DIIs) include mutual funds, banks, and insurance companies.

• Dec 2025: 20.09%
• Sept 2025: 18.61%
• Jun 2025: 17.64%
• Mar 2025: 14.60%
• Dec 2024: 13.85%

DII stake in Glenmark Pharmaceuticals Ltd has increased over time, indicating growing domestic institutional confidence.

Glenmark Pharmaceuticals Ltd Public Shareholding Trend

Public shareholding represents retail and non-institutional investors.

• Dec 2025: 14.02%
• Sept 2025: 13.97%
• Jun 2025: 15.06%
• Mar 2025: 15.56%
• Dec 2024: 15.96%

Public participation in Glenmark Pharmaceuticals Ltd has increased, indicating rising retail investor interest.

Glenmark Pharmaceuticals Ltd Government Holding

Government holding in Glenmark Pharmaceuticals Ltd currently stands at 0.04%.

Government presence indicates institutional backing and regulatory confidence.

Glenmark Pharmaceuticals Ltd Shareholding Analysis Summary

The Glenmark Pharmaceuticals Ltd shareholding pattern highlights the ownership structure and investor confidence in the company. Stable promoter holdings combined with institutional participation often indicate strong fundamentals and long-term growth potential.

Glenmark Pharmaceuticals Ltd shows strong promoter and domestic institutional confidence, which is positive for long-term investors.

Regular monitoring of the Glenmark Pharmaceuticals Ltd shareholding helps investors understand market confidence, institutional activity, and potential future stock movements.